Brazil
Egypt
Europe
Hong Kong
Malaysia
Mexico
Morocco
Philippines
Saudi Arabia
South Africa
Taiwan
Thailand
Tunisia
Turkey
UAE
USA
Vietnam
Global HQ
Biocon Q3FY21 Revenue at ₹ 1,879 Crore, Up 7%; EBITDA at ₹427 Crore; Net Profit at ₹169 Crore; Biosimilars up 11% at ₹769 Crore; Research Services up 13% at ₹585 Crore; Generics down 3% at ₹561 Crore
-
Fri, 22-Jan-2021
- Posted by: Biocon Biologics
No Comments
Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director
-
Thu, 21-Jan-2021
- Posted by: Biocon Biologics
Biocon Biologics Receives Rs 555 Cr (USD 75 Million) Capital Injection from ADQ
-
Thu, 07-Jan-2021
- Posted by: Biocon Biologics
Biocon Biologics Statement on the Status of Bevacizumab FDA Action Date in Dec 2020
-
Fri, 25-Dec-2020
- Posted by: Biocon Biologics
Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents
-
Tue, 15-Dec-2020
- Posted by: Biocon Biologics
Biocon Biologics and Mylan Receive CHMP Recommendation for Approval of Biosimilar Insulin Aspart
-
Mon, 14-Dec-2020
- Posted by: Biocon Biologics
Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs
-
Sat, 07-Nov-2020
- Posted by: Biocon Biologics
Biocon Ranked Among Top 5 Biotech Employers Globally
-
Fri, 30-Oct-2020
- Posted by: Biocon Biologics
Biocon Q2FY21 Revenue at Rs 1,760 Cr, Up 10%; EBITDA at Rs 407 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 174 Cr; Generics Up 8% at Rs 599 Cr; Biosimilars Up 11% at Rs 676 Cr; Research Services Up 12% at Rs 520 Cr.
-
Fri, 23-Oct-2020
- Posted by: Biocon Biologics
Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi
-
Thu, 08-Oct-2020
- Posted by: Biocon Biologics
